Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

What do we know about health care team effectiveness? A review of the literature.

Lemieux-Charles L, McGuire WL.

Med Care Res Rev. 2006 Jun;63(3):263-300. Review.

PMID:
16651394
2.

Beyond EBM: new directions for evidence-based public health.

McGuire WL.

Perspect Biol Med. 2005 Autumn;48(4):557-69.

PMID:
16227667
3.

Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.

Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA.

J Natl Cancer Inst. 1993 Oct 6;85(19):1558-70. Review.

PMID:
8411230
4.

DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.

Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL.

Breast Cancer Res Treat. 1993 Oct;28(1):9-20.

PMID:
8123871
5.

Glutathione transferase GST pi in breast tumors evaluated by three techniques.

Molina R, Oesterreich S, Zhou JL, Tandon AK, Clark GM, Allred DC, Townsend AJ, Moscow JA, Cowan KH, McGuire WL, et al.

Dis Markers. 1993 Sep;11(2-3):71-82.

PMID:
8261735
6.

Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.

Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V.

Cancer Res. 1993 Aug 15;53(16):3736-40.

7.
8.

Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status.

Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D.

J Cell Biochem. 1993 Jun;52(2):196-205.

PMID:
7690042
9.

Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients.

Elledge RM, Ciocca DR, Langone G, McGuire WL.

Cancer. 1993 Apr 15;71(8):2499-506.

PMID:
8095853
10.

Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications.

Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL.

J Natl Cancer Inst. 1993 Apr 7;85(7):570-4.

PMID:
8455204
11.

How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer.

Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, McGuire WL.

Cancer. 1993 Mar 15;71(6 Suppl):2157-62.

PMID:
8443766
12.

Prognostic indicators in early breast cancer.

Figueroa JA, Yee D, McGuire WL.

Am J Med Sci. 1993 Mar;305(3):176-82. Review.

PMID:
7680528
13.

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL.

J Natl Cancer Inst. 1993 Feb 3;85(3):200-6.

PMID:
8423624
14.

Estrogen receptor mutations in breast cancer.

Fuqua SA, Chamness GC, McGuire WL.

J Cell Biochem. 1993 Feb;51(2):135-9. Review.

PMID:
8440747
15.

Prognosis of breast cancer patients: how to use what?

Clark GM, McGuire WL.

Recent Results Cancer Res. 1993;127:55-60. Review. No abstract available.

PMID:
8502830
16.

Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

Elledge RM, McGuire WL.

Annu Rev Med. 1993;44:201-10. Review.

PMID:
8476242
17.

Neural Network Analysis of DNA flow cytometry histograms.

Ravdin PM, Clark GM, Hough JJ, Owens MA, McGuire WL.

Cytometry. 1993;14(1):74-80.

18.

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.

EncarnaciĆ³n CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK.

Breast Cancer Res Treat. 1993;26(3):237-46.

PMID:
8251648
19.

Prognostic significance of p53 gene alterations in node-negative breast cancer.

Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL.

Breast Cancer Res Treat. 1993;26(3):225-35.

PMID:
8251647
20.

The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain.

Fuqua SA, Allred DC, Elledge RM, Krieg SL, Benedix MG, Nawaz Z, O'Malley BW, Greene GL, McGuire WL.

Breast Cancer Res Treat. 1993;26(2):191-202.

PMID:
8219256
21.

Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.

Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL.

Anticancer Res. 1992 Nov-Dec;12(6B):1965-71.

PMID:
1363511
22.

Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM.

Cancer. 1992 Sep 15;70(6 Suppl):1775-81.

PMID:
1355403
23.

Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action.

McGuire WL Jr, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D.

J Natl Cancer Inst. 1992 Sep 2;84(17):1336-41. Erratum in: J Natl Cancer Inst 1992 Dec 2;84(23):1837.

PMID:
1379645
24.

Abnormal estrogen receptor in clinical breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):243-7. Review.

PMID:
1525064
25.

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL.

Hum Pathol. 1992 Sep;23(9):974-9.

PMID:
1355464
26.

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, et al.

J Clin Oncol. 1992 Aug;10(8):1284-91.

PMID:
1634918
27.
28.

Response of human breast cancer cells to heat shock and chemotherapeutic drugs.

Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL.

Cancer Res. 1992 Jul 1;52(13):3648-54.

29.

Prognostic factors and treatment decisions in axillary-node-negative breast cancer.

McGuire WL, Clark GM.

N Engl J Med. 1992 Jun 25;326(26):1756-61. Review. No abstract available.

PMID:
1594018
30.

Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors.

Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW.

J Clin Oncol. 1992 Jun;10(6):990-4.

PMID:
1588380
31.

Prognostic factors in breast cancer.

Elledge RM, McGuire WL, Osborne CK.

Semin Oncol. 1992 Jun;19(3):244-53. Review. No abstract available.

PMID:
1351692
32.

Optimal mastectomy timing.

McGuire WL, Hilsenbeck S, Clark GM.

J Natl Cancer Inst. 1992 Mar 4;84(5):346-8. No abstract available.

PMID:
1738187
33.

Progesterone antagonists: tumor-inhibiting potential and mechanism of action.

Michna H, Nishino Y, Neef G, McGuire WL, Schneider MR.

J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):339-48. Review.

PMID:
1562510
34.

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.

Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW.

J Clin Oncol. 1992 Feb;10(2):304-10.

PMID:
1732430
35.

Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors.

Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL.

Cancer Res. 1992 Jan 15;52(2):483-6.

36.

Treatment decisions in axillary node-negative breast cancer patients.

McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM.

J Natl Cancer Inst Monogr. 1992;(11):173-80.

PMID:
1627425
37.

Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).

Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD.

J Natl Cancer Inst Monogr. 1992;(11):167-72.

PMID:
1627424
38.

Abnormal oestrogen receptor in clinical breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

Eur J Cancer. 1992;28(2-3):309-10. Review. No abstract available.

PMID:
1591044
39.

The importance of normal and abnormal oestrogen receptor in breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

Cancer Surv. 1992;14:31-40. Review.

PMID:
1423328
40.

Why do so many prognostic factors fail to pan out?

Hilsenbeck SG, Clark GM, McGuire WL.

Breast Cancer Res Treat. 1992;22(3):197-206.

PMID:
1391986
41.

A demonstration that breast cancer recurrence can be predicted by neural network analysis.

Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WL.

Breast Cancer Res Treat. 1992;21(1):47-53.

PMID:
1391974
42.

Prognostic factors in axillary node-negative breast cancer.

Elledge RM, McGuire WL.

Cancer Treat Res. 1992;61:3-19. Review. No abstract available.

PMID:
1360238
43.

Defining the high-risk breast cancer patient.

Clark GM, McGuire WL.

Cancer Treat Res. 1992;60:161-87. Review. No abstract available.

PMID:
1355985
44.

Estrogen receptor variants in clinical breast cancer.

McGuire WL, Chamness GC, Fuqua SA.

Mol Endocrinol. 1991 Nov;5(11):1571-7. Review.

PMID:
1779964
45.

Estrogen receptor determination and long term survival of patients with carcinoma of the breast.

Crowe JP Jr, Gordon NH, Hubay CA, Shenk RR, Zollinger RM, Brumberg DJ, McGuire WL, Shuck JM.

Surg Gynecol Obstet. 1991 Oct;173(4):273-8.

PMID:
1925896
46.

The optimal timing of mastectomy: low tide or high tide?

McGuire WL.

Ann Intern Med. 1991 Sep 1;115(5):401-3. No abstract available.

PMID:
1863031
47.

Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors.

Fuqua SA, Hill SM, Chamness GC, Benedix MG, Greene GL, O'Malley BW, McGuire WL.

J Natl Cancer Inst. 1991 Aug 21;83(16):1157-60.

PMID:
1679459
48.

Hormones and breast cancer.

Sunderland MC, McGuire WL.

Trends Endocrinol Metab. 1991 Mar-Apr;2(2):72-6.

PMID:
18411169
49.

Breast cancer prognostic factors: evaluation guidelines.

McGuire WL.

J Natl Cancer Inst. 1991 Feb 6;83(3):154-5. No abstract available.

PMID:
1988696
50.

Follow-up study of HER-2/neu amplification in primary breast cancer.

Clark GM, McGuire WL.

Cancer Res. 1991 Feb 1;51(3):944-8. Review.

Supplemental Content

Loading ...
Support Center